Yoshihito Yokoyama1, Bing Xin, Tatsuhiko Shigeto, Hideki Mizunuma. 1. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. yokoyama@cc.hirosaki-u.ac.jp
Abstract
PURPOSE: We have recently reported that peroxisome proliferator-activated receptor gamma (PPARγ) ligands produce antitumor effects against human ovarian cancer in conjunction with reduction in angiogenesis and induction of apoptosis via regulating prostaglandin (PG) E(2) level. In this study, we investigated the effects of combination of ciglitazone, a PPARγ ligand, and cisplatin, a cytotoxic anti-cancer drug, on growth of ovarian cancer. METHODS: Tumor growth and survival were examined in female nu/nu mice xenografted with subcutaneous OVCAR-3 tumors or with intraperitoneal DISS tumors and treated with cisplatin alone (5 mg/kg intraperitoneally once on day 1), ciglitazone alone (15 mg/kg intraperitoneally once a week), or the combination. RESULTS: Ciglitazone alone, cisplatin alone, or their combination significantly suppressed the growth of OVCAR-3 tumors xenotransplated subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells as compared with the control. Furthermore, the combination produced a significantly greater antitumor effect than cisplatin or ciglitazone alone and also significantly prolonged the survival time as compared with cisplatin or ciglitazone alone. The combination significantly decreased PGE(2) concentration in serum as well as in ascites, reduced vascular endothelial growth factor as well as microvessel density, and induced apoptosis in solid OVCAR-3 tumor as compared with cisplatin or ciglitazone alone. The combination remarkably decreased the expression of cyclooxygenase-2 (COX-2), microsomal PG E synthase (mPGES), and PG receptor 3 (EP3) in tumors. In vitro experiment showed that ciglitazone enhances the cytotoxicity of cisplatin against ovarian cancer cells. CONCLUSION: In conclusion, the combination inhibited the growth of ovarian cancer in conjunction with reduction in angiogenesis and induction of apoptosis resulting from suppression of PGE(2) activation through decreasing the expression of COX-2, mPGES, and EP3. The inhibitory effect of this combination treatment on growth of ovarian cancer suggests a potential to lead a novel therapeutic strategy against ovarian cancer.
PURPOSE: We have recently reported that peroxisome proliferator-activated receptor gamma (PPARγ) ligands produce antitumor effects against humanovarian cancer in conjunction with reduction in angiogenesis and induction of apoptosis via regulating prostaglandin (PG) E(2) level. In this study, we investigated the effects of combination of ciglitazone, a PPARγ ligand, and cisplatin, a cytotoxic anti-cancer drug, on growth of ovarian cancer. METHODS:Tumor growth and survival were examined in female nu/nu mice xenografted with subcutaneous OVCAR-3 tumors or with intraperitoneal DISS tumors and treated with cisplatin alone (5 mg/kg intraperitoneally once on day 1), ciglitazone alone (15 mg/kg intraperitoneally once a week), or the combination. RESULTS:Ciglitazone alone, cisplatin alone, or their combination significantly suppressed the growth of OVCAR-3 tumors xenotransplated subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells as compared with the control. Furthermore, the combination produced a significantly greater antitumor effect than cisplatin or ciglitazone alone and also significantly prolonged the survival time as compared with cisplatin or ciglitazone alone. The combination significantly decreased PGE(2) concentration in serum as well as in ascites, reduced vascular endothelial growth factor as well as microvessel density, and induced apoptosis in solid OVCAR-3 tumor as compared with cisplatin or ciglitazone alone. The combination remarkably decreased the expression of cyclooxygenase-2 (COX-2), microsomal PG E synthase (mPGES), and PG receptor 3 (EP3) in tumors. In vitro experiment showed that ciglitazone enhances the cytotoxicity of cisplatin against ovarian cancer cells. CONCLUSION: In conclusion, the combination inhibited the growth of ovarian cancer in conjunction with reduction in angiogenesis and induction of apoptosis resulting from suppression of PGE(2) activation through decreasing the expression of COX-2, mPGES, and EP3. The inhibitory effect of this combination treatment on growth of ovarian cancer suggests a potential to lead a novel therapeutic strategy against ovarian cancer.
Authors: Rex C Haydon; Lan Zhou; Tao Feng; Benjamin Breyer; Hongwei Cheng; Wei Jiang; Akira Ishikawa; Terrance Peabody; Anthony Montag; Michael A Simon; Tong-Chuan He Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Yuzhi Yin; Robert G Russell; Luis E Dettin; Renkui Bai; Zhi-Liang Wei; Alan P Kozikowski; Levy Kopelovich; Levy Kopleovich; Robert I Glazer Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: Matthew C Catley; Joanna E Chivers; Lisa M Cambridge; Neil Holden; Donna M Slater; Karl J Staples; Martin W Bergmann; Peter Loser; Peter J Barnes; Robert Newton Journal: FEBS Lett Date: 2003-07-17 Impact factor: 4.124
Authors: T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols Journal: Cancer Res Date: 1983-11 Impact factor: 12.701
Authors: M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739
Authors: Anna Wilk; Katarzyna Urbanska; Maja Grabacka; Jennifer Mullinax; Cezary Marcinkiewicz; David Impastato; John J Estrada; Krzysztof Reiss Journal: Cell Cycle Date: 2012-07-15 Impact factor: 4.534
Authors: Christina K Cramer; Natalie Alphonse-Sullivan; Scott Isom; Linda J Metheny-Barlow; Tiffany L Cummings; Brandi R Page; Doris R Brown; Arthur W Blackstock; Ann M Peiffer; Roy E Strowd; Stephen Rapp; Glenn J Lesser; Edward G Shaw; Michael D Chan Journal: J Cancer Res Clin Oncol Date: 2018-11-12 Impact factor: 4.553
Authors: Anna Wilk; Dorota Wyczechowska; Adriana Zapata; Matthew Dean; Jennifer Mullinax; Luis Marrero; Christopher Parsons; Francesca Peruzzi; Frank Culicchia; Augusto Ochoa; Maja Grabacka; Krzysztof Reiss Journal: Mol Cell Biol Date: 2014-10-20 Impact factor: 4.272
Authors: Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami Journal: Cancer Metastasis Rev Date: 2012-06 Impact factor: 9.264